Meeder Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Meeder Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$340K	Buy	10,502 +5,493	+110%	+$210K	0.02%	256
2026 Q2	$186K	Buy	+5,009	New	+$162K	0.01%	306
2022 Q3	–	Sell	-33	Closed	-$1K	–	2169
2022 Q2	$1K	Hold	33	–	–	﹤0.01%	1993
2022 Q1	$1K	Hold	33	–	–	﹤0.01%	2154
2021 Q4	$1K	Buy	+33	New	+$1.44K	﹤0.01%	1013
2018 Q3	–	Sell	-126	Closed	-$954	–	1561
2018 Q2	$954	Buy	126 +88	+232%	+$1.18K	﹤0.01%	1504
2018 Q1	$1K	Buy	38 +14	+58%	+$542	﹤0.01%	1443
2017 Q4	$1K	Buy	+24	New	+$1.03K	﹤0.01%	1556
2017 Q3	–	Sell	-63	Closed	-$2K	–	1641
2017 Q2	$2K	Sell	63 -56	-47%	-$2.48K	﹤0.01%	1388
2017 Q1	$6K	Sell	119 -230	-66%	-$12K	﹤0.01%	996
2016 Q4	$19K	Buy	+349	New	+$19.9K	﹤0.01%	663

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Meeder Asset Management's CLDX Position: Q3 2026 in Review

Meeder Asset Management increased its Celldex Therapeutics (CLDX) stake by 110% in Q3 2026, buying an estimated $210K and bringing the position to 10,502 shares worth $340K. The position accounts for 0.02% of the portfolio, ranked #256.

Meeder Asset Management first reported a position in CLDX in Q4 2016 and has held it in 11 quarters since. 125 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

Meeder Asset Management held 10,502 shares of Celldex Therapeutics worth $340K as of Q3 2026.
Meeder Asset Management bought 5,493 Celldex Therapeutics shares in Q3 2026, an estimated $210K.
Celldex Therapeutics made up 0.02% of Meeder Asset Management's portfolio in Q3 2026, its #256 holding.
Meeder Asset Management first reported a position in Celldex Therapeutics in Q4 2016 and has held it in 11 quarters since.
125 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Meeder Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.